Oculis Holding AG Ordinary shares (NASDAQ: OCS) — Perfil da empresa, notícias e dados financeiros
Oculis develops ophthalmic treatments aimed at improving sight and addressing conditions like diabetic macular edema.
Oculis Holding AG Ordinary shares
Oculis (NASDAQ:OCS) focuses on developing ophthalmic treatments that aim to improve the sight and lives of patients globally. Their innovative projects include therapies for conditions like diabetic macular edema and dry eye disease, showcasing a dedication to addressing major eye health challenges. Oculis' objectives revolve around pushing the boundaries of science to create effective, accessible treatments. With a commitment to leveraging cutting-edge technology and research, the company works tirelessly to bring new solutions to the forefront of eye care.
Resumo
Operações
Produtos e/ou serviços de Oculis Holding AG Ordinary shares
- A topical eye drop treatment aiming to reduce the progression of diabetic retinopathy and prevent vision loss.
- An innovative solution for treating dry eye disease, enhancing patient comfort and reducing symptoms.
- A non-invasive therapy for age-related macular degeneration to improve visual acuity and slow disease progression.
- A novel eye drop for the treatment of anterior uveitis, aiming to reduce inflammation and pain without the side effects of current therapies.
- A groundbreaking solution for patients with glaucoma, focusing on reducing intraocular pressure through a non-surgical approach.
- A breakthrough therapy for the treatment of corneal edema, offering patients rapid relief and improved vision.
equipe executiva do Oculis Holding AG Ordinary shares
- Riad SherifCEO & Director
- Sylvia CheungChief Financial Officer
- Gudrun BachmannChief Technology Officer
- Ramin TadayoniChief Scientific Officer
- Katie KazemChief Legal Officer
- Virginia R. DeanChief Human Resources Officer
- Páll Ragnar JóhannessonChief Business Officer
- Rebecca WeilChief Commercial Officer
- Snehal ShahPresident of Research & Development
- Sharon KlierChief Development Officer
Últimas notícias sobre a Oculis Holding AG Ordinary shares
Oculis reports Phase 2 nerve injury biomarker findings
United StatesOculis to present Phase 2 Privosegtor biomarker data
United StatesOculis completes randomization of 176 trial patients
United StatesOculis schedules Licaminlimab presentation ahead of trial results
United StatesOculis joins MS campaign with vision focus
United StatesOculis starts Privosegtor optic neuritis trial
United States
Principais indicadores financeiros
Resultados divulgados pela Oculis Holding AG Ordinary shares, em CHF.
- Cap. de mercado
- 422,9 mi
- Receita (TTM)
- 937 mil
- P/L
- —
- LPA (diluído, TTM)
- -1.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -79,1 mi | -94,5 mi | |
| 686 mil | -73,2 mi | -85,8 mi | |
| 883 mil | -80,7 mi | -88,8 mi | |
| 912 mil | -32,4 mi | -38,7 mi |